Similar articles for PMID: 24336635

Year	Number of Results
2010	1
2011	3
2012	5
2013	14
2014	13
2015	7
2016	3
2017	6
2018	2
2019	3
2022	3
2024	0

1

Brain-metastatic triple-negative breast cancer cells regain growth ability by altering gene expression patterns.

Choi YK, Woo SM, Cho SG, Moon HE, Yun YJ, Kim JW, Noh DY, Jang BH, Shin YC, Kim JH, Shin HD, Paek SH, Ko SG. Choi YK, et al. Cancer Genomics Proteomics. 2013 Nov-Dec;10(6):265-75. Cancer Genomics Proteomics. 2013. PMID: 24336635

2

NOTCH4 is a potential therapeutic target for triple-negative breast cancer.

Nagamatsu I, Onishi H, Matsushita S, Kubo M, Kai M, Imaizumi A, Nakano K, Hattori M, Oda Y, Tanaka M, Katano M. Nagamatsu I, et al. Anticancer Res. 2014 Jan;34(1):69-80. Anticancer Res. 2014. PMID: 24403446

3

microRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells.

Ren Y, Han X, Yu K, Sun S, Zhen L, Li Z, Wang S. Ren Y, et al. Mol Med Rep. 2014 Jul;10(1):315-21. doi: 10.3892/mmr.2014.2222. Epub 2014 May 8. Mol Med Rep. 2014. PMID: 24821285

4

Gene expression profiling of brain metastatic cell from triple negative breast cancer: Understanding the molecular events.

Zhou L, Gao HF, Liu DS, Feng JY, Gao DD, Xia W. Zhou L, et al. Gene. 2018 Jan 15;640:21-27. doi: 10.1016/j.gene.2017.10.019. Epub 2017 Oct 9. Gene. 2018. PMID: 29024707

5

Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer.

Zhang C, Han Y, Huang H, Min L, Qu L, Shou C. Zhang C, et al. Int J Oncol. 2014 Jun;44(6):2025-33. doi: 10.3892/ijo.2014.2352. Epub 2014 Mar 20. Int J Oncol. 2014. PMID: 24676531

6

MicroRNAs-mediated cell fate in triple negative breast cancers.

Sui X, Wang X, Han W, Li D, Xu Y, Lou F, Zhou J, Gu X, Zhu J, Zhang C, Pan H. Sui X, et al. Cancer Lett. 2015 May 28;361(1):8-12. doi: 10.1016/j.canlet.2015.02.048. Epub 2015 Mar 3. Cancer Lett. 2015. PMID: 25748387 Review.

7

Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.

Kim EM, Mueller K, Gartner E, Boerner J. Kim EM, et al. J Surg Res. 2013 Nov;185(1):231-9. doi: 10.1016/j.jss.2013.06.041. Epub 2013 Jul 17. J Surg Res. 2013. PMID: 23899511

8

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.

Shapira I, Lee A, Vora R, Budman DR. Shapira I, et al. Crit Rev Oncol Hematol. 2013 Nov;88(2):284-92. doi: 10.1016/j.critrevonc.2013.05.003. Epub 2013 Jun 5. Crit Rev Oncol Hematol. 2013. PMID: 23755891 Review.

9

Triple-negative breast cancer survival in Iranian patients.

Aghili M, Lashkari M, Farrokhpey AH, Izadi S. Aghili M, et al. Acta Med Iran. 2013 Sep 9;51(8):560-6. Acta Med Iran. 2013. PMID: 24026994 Free article.

10

Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer.

Yotsumoto F, Tokunaga E, Oki E, Maehara Y, Yamada H, Nakajima K, Nam SO, Miyata K, Koyanagi M, Doi K, Shirasawa S, Kuroki M, Miyamoto S. Yotsumoto F, et al. Mol Cancer Res. 2013 May;11(5):506-17. doi: 10.1158/1541-7786.MCR-12-0428. Epub 2013 Feb 26. Mol Cancer Res. 2013. PMID: 23443317

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

51 results

Results by year